항독소 시장 보고서 : 생물종, 항독소 유형, 작용기서, 최종사용자, 지역별(2024-2032년)

The global anti-venom market size reached US$ 1,169.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,003.5 Million by 2032, exhibiting a growth rate (CAGR) of 6% during 2024-2032. The rising incidences of snake bites and scorpion stings, the implementation of favorable government initiatives, and ongoing innovations in the industry represent some of the key factors driving the market.

Anti-venom, also known as venom antiserum, refers to a type of medication used to treat the effects of venomous bites or stings from animals, including snakes, spiders, scorpions, and certain marine creatures such as jellyfish or cone snails. It is obtained by extracting venom from the offending animal and then injecting small amounts of the venom into animals, such as horses, sheep, or goats, whose immune systems produce antibodies that are harvested and purified to create anti-venom. Anti-venom neutralizes the toxins and counteracts the effects of the venom, preventing them from causing life-threatening complications such as respiratory failure or organ damage. It is extensively adopted across the globe in treating venomous bites and stings, depending on their history, examination, and geographic, clinical, and pathologic factors.

Anti-Venom Market Trends:

The rise in cases of venomous bites and stings across the world, particularly in rural and tropical regions and among agricultural workers and hunters, represents one of the prime factors driving the market growth. Besides this, the escalating consumer awareness of the importance of snake bite prevention and easy product availability at an affordable price is creating a favorable outlook for the market. Moreover, the implementation of numerous government initiatives to combat snake bites, such as education and training programs, and intensive investments in research and development (R&D) activities of new anti-venom products are contributing to the market growth. In addition to this, with the rising demand for animal-based protein, there is an increase in the number of livestock and other animals at risk of snake bites, which, in turn, is presenting remunerative growth opportunities for the market. Concurrent with this, the rising popularity of traveling and exploring exotic destinations, such as islands, deserts, jungles, and safaris, that puts tourists at risk of snake bites and other venomous animal encounters is acting as another significant growth-inducing factor. Furthermore, numerous technological advancements in the biotechnology and healthcare industries and ongoing innovative improvements in manufacturing technology, allowing for the production of more effective and efficient anti-venom products, are positively impacting the market growth. Apart from this, the launch of various rapid snake venom detection kits, which utilize a rapid enzyme immunoassay to detect and identify snake venom through samples taken from bite sites, urine, plasma, blood, or other tissues and body fluids, is propelling the market forward.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-venom market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on species, anti-venom type, mode of action and end user.

Species Insights:

Snake

Scorpion

Spider

Others

The report has provided a detailed breakup and analysis of the anti-venom market based on the species. This includes snake, scorpion, spider, and others. According to the report, snake represented the largest segment.

Anti-venom Type Insights:

Polyvalent Anti-venom

Monovalent Anti-venom

A detailed breakup and analysis of the anti-venom market based on the anti-venom type has also been provided in the report. This includes polyvalent and monovalent anti-venom. According to the report, polyvalent anti-venom accounted for the largest market share.

Mode of Action Insights:

Cytotoxic

Neurotoxic

Haemotoxic

Cardiotoxic

Myotoxic

Others

The report has provided a detailed breakup and analysis of the anti-venom market based on the mode of action. This includes cytotoxic, neurotoxic, haemotoxic, cardiotoxic, myotoxic, and others. According to the report, neurotoxic represented the largest segment.

End User Insights:

Hospitals

Clinics

Ambulatory Surgical Centers

A detailed breakup and analysis of the anti-venom market based on the end user has also been provided in the report. This includes hospitals, clinics, and ambulatory surgical centers. According to the report, hospitals accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-venom. Some of the factors driving the North America anti-venom market included the increasing incidence of snake bites, the introduction of numerous favorable government initiatives, and the thriving travel and tourism sector.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global anti-venom market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc., and Rare Disease Therapeutics Inc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

• 1. What was the size of the global anti-venom market in 2023?
• 2. What is the expected growth rate of the global anti-venom market during 2024-2032?
• 3. What has been the impact of COVID-19 on the global anti-venom market?
• 4. What are the key factors driving the global anti-venom market?
• 5. What is the breakup of the global anti-venom market based on the species?
• 6. What is the breakup of the global anti-venom market based on the anti-venom type?
• 7. What is the breakup of the global anti-venom market based on the mode of action?
• 8. What is the breakup of the global anti-venom market based on the end user?
• 9. What are the key regions in the global anti-venom market?
• 10. Who are the key players/companies in the global anti-venom market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Anti-venom Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Species

• 6.1 Snake
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Scorpion
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Spider
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Anti-venom Type

• 7.1 Polyvalent Anti-venom
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Monovalent Anti-venom
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Mode of Action

• 8.1 Cytotoxic
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Neurotoxic
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Haemotoxic
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Cardiotoxic
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Myotoxic
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Others
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast

9 Market Breakup by End User

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Clinics
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Ambulatory Surgical Centers
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Bharat Serums and Vaccines Limited (BSV)
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Boehringer Ingelheim International GmbH
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Boston Scientific Corporation
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 CSL Limited
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Haffkine Bio-Pharmaceutical Corporation Limited
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Incepta Pharmaceuticals Limited
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Merck & Co. Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Merck KGaA
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 MicroPharm Limited
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Pfizer Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Rare Disease Therapeutics Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio